Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors.

Date publication

juin 2023

Journal

European urology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr MICHEAU Olivier

Tous les auteurs :
Groeneveld CS, Sanchez-Quiles V, Dufour F, Shi M, Dingli F, Nicolle R, Chapeaublanc E, Poullet P, Jeffery D, Krucker C, Maillé P, Vacherot F, Vordos D, Benhamou S, Lebret T, Micheau O, Zinovyev A, Loew D, Allory Y, de Reyniès A, Bernard-Pierrot I, Radvanyi F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37380559

Résumé

Molecular understanding of muscle-invasive (MIBC) and non-muscle-invasive (NMIBC) bladder cancer is currently based primarily on transcriptomic and genomic analyses.

Mots clés

Apoptosis, Bladder cancer, FGFR3, Proteogenomics, Proteomics, Tumor necrosis factor–related apoptosis-inducing ligand, Tumor necrosis factor–related apoptosis-inducing ligand receptors

Référence

Eur Urol. 2023 06 27;: